

calculation of consolidated EBIT and EBITDA



annual, fiscal 2013 to present

(millions) (unaudited)	2017 ^(b)	2016	2015 ^(c)	2014	2013 ^(d)
Net earnings from continuing operations	\$ 2,928	\$ 2,669	\$ 3,321	\$ 2,449	\$ 2,694
+ Provision for income taxes	718	1,296	1,602	1,204	1,427
+ Net interest expense	666	1,004	607	882	1,049
Earnings from continuing operations before interest expense and income taxes (EBIT)	4,312	4,969	5,530	4,535	5,170
+ Depreciation and amortization ^(a)	2,445	2,298	2,213	2,129	1,996
EBITDA	\$ 6,757	\$ 7,267	\$ 7,743	\$ 6,664	\$ 7,166

^(a) Represents total depreciation, including amounts classified within depreciation and amortization and within cost of sales on our Consolidated Statements of Operations.

^(b) 2017 consisted of 53 weeks compared with 52 weeks in the comparable prior-year periods.

^(c) Includes a \$620 million gain on sale of our former pharmacy and clinic businesses.

^(d) Includes a \$391 million gain on sale of our U.S. credit card receivables portfolio.